Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific Inc. $TMO is Broyhill Asset Management LLC’s 10th Largest Position
Broyhill Asset Management LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 530.0% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,024 shares of the medical research company's stock after buying an additional 5,909 shares during
Thermo Fisher Scientific Inc. $TMO Shares Sold by Brown Brothers Harriman & Co.
Brown Brothers Harriman and Co. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 1.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 516,385 shares of the medical research company's stock after selling 6,201 shares during
Glenmede Investment Management LP Sells 29,195 Shares of Thermo Fisher Scientific Inc. $TMO
Glenmede Investment Management LP trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 25.7% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,444 shares of the medical research company's stock after selling 29,195 shares during
Is This the Right Time to Hold Thermo Fisher Stock in Your Portfolio?
TMO's acquisitions and resilient pharma, biotech and diagnostics demand support growth, but currency swings and fierce competition remain risks.
Thermo Fisher Scientific Inc. (TMO) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Thermo Fisher Scientific Inc. (TMO) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Thermo Fisher Scientific: Recovery In Life Sciences Solutions
Thermo Fisher Scientific is reiterated as a 'buy' with a fair value estimate of $619 per share, reflecting confidence in its recovery and strategic positioning. TMO's acquisition of Clario Holdings for $8.875 billion is expected to enhance recurring revenue, accelerate organic growth, and support future AI-driven clinical trial solutions. Management guides for 3%-4% organic revenue growth and 6%-8% adjusted EPS growth in FY26, underpinned by improving biotech funding and market sentiment.
Thermo Fisher: The Market Is Missing The Point, This Pullback Is A Buy (Rating Update)
Thermo Fisher delivered strong Q1 results, beating expectations with revenue of $12.21B (+7% YoY) and EPS of $6.57 (+8%). I reaffirm my strong buy rating on TMO, setting a target price of $668 per share, citing resilient margins and competitive positioning. TMO's 2026 guidance calls for $46.3B-$47.2B revenue (+4-6%) and EPS of $24.22-$24.80 (+6-8%), with organic growth of 4%.
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Thermo Fisher stock slides on cautious profit guidance
Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) delivered a fourth quarter earnings beat, but its shares moved lower as investors focused on margin pressures and cautious earnings guidance for 2026. The life sciences tools and diagnostics company guided 2026 revenue to a range of $46.3 billion to $47.2 billion, implying 4% to 6% growth and organic growth of 3% to 4%, broadly in line with consensus expectations and indicating continued modest demand across biopharma and life sciences end markets.
Thermo Fisher (TMO) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thermo Fisher's Q4 Earnings & Revenues Top Estimates, Stock Climbs
TMO beats Q4 EPS and revenue estimates, posts 7.1% sales growth, and sees shares rise after results despite margin pressure.
Thermo Fisher Scientific (TMO) Beats Q4 Earnings and Revenue Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.57 per share, beating the Zacks Consensus Estimate of $6.43 per share. This compares to earnings of $6.1 per share a year ago.
